| Identification | Back Directory | [Name]
[1,1′-Biphenyl]-3-carbonitrile, 5-[[1-[(4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]-3′-methyl- | [CAS]
3033486-43-7 | [Synonyms]
[1,1′-Biphenyl]-3-carbonitrile, 5-[[1-[(4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]-3′-methyl- | [Molecular Formula]
C24H18F3N5O3 | [MOL File]
3033486-43-7.mol | [Molecular Weight]
481.43 |
| Hazard Information | Back Directory | [Uses]
ZLM-66 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTIs) with an IC50 of 41 nM for wild-type (WT) HIV-1 reverse transcriptase and an EC50 value of 13 nM for wild-type HIV-1. ZLM-66 is a Doravirine (HY-16767) analogs. ZLM-66 can be used for the research of AIDS[1]. | [in vivo]
Zlm-66 (1-5 mg/kg; i.v. and p.o. once) shows good druggability and have a good effect in vivo after oral administration[1].
1.19 Pharmacokinetic Parameters of ZLM-66 in rat[1]. | Rat IV 1 mg/kg | Rat PO 5 mg/kg | | T1/2 (h) | 1.90±0.28 | 8.45±4.88 | | Tmax (h) | 0.08±0.00 | 6.67±1.15 | | Cmax (ng/mL) | 468.67±63.09 | 583.33±290.11 | | AUC0-t (h*ng/ml) | 891.94±79.30 | 4983.22±3220.11 | | AUC0-∞ (h*ng/ml) | 940.41±105.00 | 6594.05±1547.74 | | CL (ml/h/kg) | 1072.31±120.40 | 791.14±210.66 |
/tr>
| MRT0-t (h) | 2.03±0.2 | 6.79±1.90 | /tr>
| MRT0-∞ (h) | 2.48±0.35 | 13.92±6.44 | | F (%) | | 140.24 |
| Animal Model: | Six- to 8-week-old male Sprague-Dawley rats (180?230 g)[1] | | Dosage: | 1, 5 mg/kg | | Administration: | Intravenous injection, oral gavage; 1-5 mg/kg; once | | Result: | Possed a better in vivo effect of oral administration with half-life, plasma clearance and oral bioavailability of 8.45 h, 791.14 ml/h/kg and 140.24% respectively. |
| [IC 50]
HIV-1 (WT): 13 nM (EC50); HIV-1 (K103N): 13 nM (EC50); HIV-1 (L100I): 24 nM (EC50); HIV-1 (E138K): 25 nM (EC50); HIV-1 (Y181C): 58 nM (EC50); HIV-1 (K103N+Y181C): 260 nM (EC50); HIV-1 (F227L+V106A): 27530 nM (EC50) | [References]
[1] Zhao LM, et al. Discovery of novel biphenyl-substituted pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with promising oral bioavailability. Eur J Med Chem. 2022 Jun 30;240:114581. DOI:10.1016/j.ejmech.2022.114581 |
|
|